ACADIA Pharmaceuticals (ACAD) AI Stock Analysis

• Market Cap: $4.06B
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): 15.5
• Beta (1Y): 1.16
• Revenue Growth: 12.69%
• EPS Growth: 100.80%
• Country: US
• Employees: 653
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.42
• Shares Outstanding: 169,181,820
• 10 Day Avg. Volume: 1,837,549
• 30 Day Avg. Volume: 1,935,672
• PEG Ratio: -0.03
• Price to Book (P/B): 4.15
• Price to Sales (P/S): 3.17
• P/FCF Ratio: 19.34
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 2.72
• Enterprise Value/Gross Profit: 2.96
• Enterprise Value/Ebitda: 24.29
• 1Y Price Target: $30.35
• Price Target Upside: 26.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18
• EPS Forecast (FY): 0.79
• Revenue Forecast (FY): $1.08B

• Rating: 73 Outperform
• Price Target: $24.00 ▼(-0.08% Downside)

ACADIA Pharmaceuticals' strong financial performance and strategic growth initiatives, particularly in DAYBUE and NUPLAZID, are key strengths. The company's valuation suggests potential upside, though technical indicators show a neutral trend. Challenges in market penetration and rising R&D expenses are notable risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates effective market strategies and product demand, supporting long-term financial stability and expansion.

Pipeline Advancements

Advancing pipeline with new studies enhances future growth prospects and strengthens competitive positioning in CNS disorders.

Cash Position

A strong cash position provides financial flexibility for strategic investments and R&D, supporting sustainable growth.

Negative Factors

DAYBUE Market Penetration Challenges

Low market penetration for DAYBUE could limit revenue potential and impact long-term growth if not addressed effectively.

Disappointment in Canada

Reimbursement challenges in Canada may hinder DAYBUE's international expansion and revenue diversification efforts.

R&D Expense Increase

Rising R&D expenses could pressure margins and profitability, necessitating successful outcomes from pipeline investments.

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company is primarily engaged in the research and development of drugs for the treatment of conditions such as Parkinson's disease psychosis and schizophrenia. Its core product, NUPLAZID (pimavanserin), is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and is marketed in the United States.

How the Company Makes Money

ACADIA Pharmaceuticals generates revenue primarily through the sale of its flagship product, NUPLAZID. The company earns income from product sales to healthcare providers and pharmacies. Additionally, ACADIA may receive milestone payments and royalties from partnerships with other pharmaceutical companies involved in the development and commercialization of complementary therapies. The company also engages in research collaborations and licensing agreements that can provide additional revenue streams. Factors contributing to its earnings include the growth in demand for treatments for CNS disorders, successful marketing strategies, and potential new product approvals or expansions in indications for existing drugs.

ACADIA Pharmaceuticals Financial Statement Overview

Summary

ACADIA Pharmaceuticals demonstrates strong profitability and revenue growth, with significant improvements in net income and cash flow generation. The balance sheet reflects low leverage and a solid equity base, though there is room for enhancing operational efficiencies and cash flow conversion.

Income Statement

ACADIA Pharmaceuticals has shown a strong gross profit margin of over 91% consistently, indicating efficient cost management. The net profit margin has improved significantly, turning positive in the TTM period, reflecting enhanced profitability. Revenue growth is steady, with a notable increase in the TTM period. However, EBIT and EBITDA margins are relatively low, suggesting room for operational efficiency improvements.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage and financial stability. Return on equity has turned positive, showcasing improved profitability and shareholder returns. The equity ratio suggests a solid capital structure, though there is potential to optimize asset utilization further.

Cash Flow

Operating and free cash flows have improved, with positive growth rates indicating better cash generation capabilities. The operating cash flow to net income ratio is below 1, suggesting that not all net income is translating into cash flow, which could be a concern. However, the free cash flow to net income ratio is close to 1, indicating efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.05B	957.80M	726.44M	517.24M	484.14M	441.75M
Gross Profit	962.54M	875.96M	680.71M	507.07M	465.00M	421.20M
EBITDA	117.30M	100.16M	-67.83M	-221.57M	-167.09M	-283.65M
Net Income	261.17M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M
Balance Sheet
Total Assets	1.33B	1.19B	748.96M	587.81M	700.12M	782.62M
Cash, Cash Equivalents and Short-Term Investments	847.02M	755.99M	438.87M	416.82M	520.71M	631.96M
Total Debt	54.81M	51.99M	57.20M	62.00M	64.43M	44.46M
Total Liabilities	413.50M	454.96M	317.20M	187.40M	159.23M	155.61M
Stockholders Equity	917.27M	732.79M	431.75M	400.41M	540.89M	627.01M
Cash Flow
Free Cash Flow	197.81M	157.20M	-23.35M	-114.03M	-126.78M	-143.75M
Operating Cash Flow	198.95M	157.72M	16.70M	-114.03M	-125.66M	-136.17M
Investing Cash Flow	-124.55M	-30.54M	32.00M	73.24M	-71.10M	192.51M
Financing Cash Flow	29.19M	6.84M	25.13M	8.20M	18.16M	81.00M

ACADIA Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACAD, the sentiment is Positive. The current price of 24.02 is above the 20-day moving average (MA) of 22.47, above the 50-day MA of 22.42, and above the 200-day MA of 20.69, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 61.22 is Neutral, neither overbought nor oversold. The STOCH value of 87.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACAD.

ACADIA Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	80 Outperform	$5.89B	30.18	19.66%	―	54.51%	275.94%
PTCT	74 Outperform	$6.05B	8.80	―	―	97.54%	―
ACAD	73 Outperform	$4.06B	15.45	34.95%	―	12.69%	100.80%
ARWR	57 Neutral	$5.23B	-29.96	-34.80%	―	2816.21%	73.33%
ACLX	52 Neutral	$5.21B	―	-47.18%	―	-76.96%	-425.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLTX	41 Neutral	$911.44M	―	-54.17%	―	―	-157.74%

ACADIA Pharmaceuticals Corporate Events

ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights

ACADIA Pharmaceuticals Inc. recently conducted its third-quarter 2025 earnings call, revealing a strong performance characterized by robust revenue growth and strategic investments. The company reported significant sales increases for its key products, DAYBUE and NUPLAZID, while also advancing its pipeline. However, challenges such as DAYBUE’s market penetration and increased R&D expenses were also highlighted.

Acadia Pharmaceuticals Reports Strong Q3 2025 Growth

Acadia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative treatments for neurological and rare diseases, with a portfolio that includes FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome.

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204

Study Overview: ACADIA Pharmaceuticals Inc. is conducting a clinical study titled ‘A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer’s Disease Psychosis.’ The study aims to evaluate the efficacy and safety of ACP-204, a treatment for Alzheimer’s Disease Psychosis (ADP), through three independent substudies. This research is significant as it addresses a critical need for effective treatments in ADP.

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204

Study Overview: ACADIA Pharmaceuticals Inc. is conducting a clinical study titled ‘A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer’s Disease Psychosis.’ The study aims to evaluate the efficacy and safety of ACP-204, a treatment for Alzheimer’s Disease Psychosis (ADP), through three independent substudies. This research is significant as it addresses a critical need for effective treatments in ADP.

ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis

Study Overview: ACADIA Pharmaceuticals Inc. is conducting a Phase 2 clinical study titled ‘A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP).’ The study aims to evaluate the efficacy and safety of ACP-204 in treating psychosis associated with Lewy Body Dementia, a significant condition affecting cognitive and motor functions in adults.

ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment

ACADIA Pharmaceuticals Inc. is conducting a 52-week open-label extension study titled ‘ACP-204 in Adults With Alzheimer’s Disease Psychosis.’ The study aims to assess the long-term safety and tolerability of ACP-204, a promising treatment for Alzheimer’s Disease Psychosis (ADP). This research holds significant potential for improving the quality of life for individuals affected by ADP.

ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment

ACADIA Pharmaceuticals Inc. is conducting a Phase 3, Open-Label Extension Study titled ’52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)’. The study aims to evaluate the long-term safety and efficacy of ACP-204, a drug intended to treat psychosis in adults with Lewy Body Dementia. This study is significant as it addresses a critical need for effective treatments in this patient population.

ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings

ACADIA Pharmaceuticals Inc. recently held its earnings call, revealing a positive sentiment driven by strong revenue growth and strategic initiatives. The company showcased impressive sales figures for its key products, DAYBUE and NUPLAZID, and highlighted successful direct-to-consumer campaigns. Despite concerns regarding increased SG&A expenses and risks associated with pipeline development, the overall outlook remains optimistic.

Acadia Pharmaceuticals Reports Strong Q2 2025 Growth

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological and rare diseases. The company is known for its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.